Literature DB >> 29644525

Determination of NF-κB and RANKL levels in peripheral blood osteoclast precursor cells in chronic kidney disease patients.

Gülcan Güneş1, Nil Doğruer Ünal2, Gülçin Eskandari1, Ahmet Kiykim3, Özlem Bölgen Çimen4, Gülhan Temel5, Mehmet Burak Y Çimen1.   

Abstract

PURPOSE: Chronic kidney disease (CKD) is a progressive condition characterized by irreversible loss of functional nephron mass due to variety of causes; an inevitable complication of CKD is metabolic bone disease, and this pathology is called as renal osteodystrophy (ROD). In this study, we aimed to determine the levels of serum sRANKL and intracellular NF-κB levels in peripheral blood osteoclast precursor cells in patients with stage 3 CKD.
MATERIALS AND METHODS: Forty-one male patients aged 35-60 with CKD identified as stage 3 according to GFR calculated on the basis of creatinine values and 27 healthy male subjects with age ranging from 40 to 60 as control group were included in this study. Levels of biochemical parameters, vitamin D3, parathyroid hormone, bone mineral density, sRANKL and NF-κB were determined by using photometric, electrochemiluminescence, HPLC, ELISA and flow cytometric methods in control and patient groups, respectively.
RESULTS: When stage 3 CKD patients were compared with controls, patients with stage 3 CKD had statistically significantly higher iPTH levels, but they had statistically significantly lower vitamin D3 levels. However, the other biochemical parameters, bone mineral density, sRANKL and NF-κB levels did not reveal any significance.
CONCLUSION: In conclusion, vitamin D3 and iPTH levels seem to be important parameters for evaluating the early stages of ROD. The lack of statistically significant differences in the levels of sRANKL and NF-κB suggests that these parameters are not sufficient in the evaluation of bone metabolism in the early stages of renal failure.

Entities:  

Keywords:  Chronic kidney disease; NF-κB; Renal osteodystrophy; sRANKL

Mesh:

Substances:

Year:  2018        PMID: 29644525     DOI: 10.1007/s11255-018-1859-0

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  33 in total

Review 1.  The use of flow cytometry in the diagnosis and monitoring of malignant hematological disorders.

Authors:  M S Ward
Journal:  Pathology       Date:  1999-11       Impact factor: 5.306

2.  Biochemical indices of renal osteodystrophy in dialysis patients on the island of Malta.

Authors:  Ian Galea; Emanuel Farrugia
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

Review 3.  The need to treat predialysis patients.

Authors:  N A Hamdy
Journal:  Nephrol Dial Transplant       Date:  1995       Impact factor: 5.992

4.  Age and gender predict OPG level and OPG/sRANKL ratio in maintenance hemodialysis patients.

Authors:  B Naumnik; K Klejna; E Koc-Żórawska; M Myśliwiec
Journal:  Adv Med Sci       Date:  2013       Impact factor: 3.287

5.  The effect of RANKL and OPG on bone mineral density in pre-dialysis chronic renal failure.

Authors:  A Fahrleitner-Pammer; H Dobnig; H P Dimai; H Holzer; T Benesch; K Borchhardt; D Cejka; M Haas
Journal:  Clin Nephrol       Date:  2009-06       Impact factor: 0.975

Review 6.  Bone loss in chronic kidney disease: Quantity or quality?

Authors:  Cai-Mei Zheng; Jin-Quan Zheng; Chia-Chao Wu; Chien-Lin Lu; Jia-Fwu Shyu; Hsu Yung-Ho; Mei-Yi Wu; I-Jen Chiu; Yuan-Hung Wang; Yuh-Feng Lin; Kuo-Cheng Lu
Journal:  Bone       Date:  2016-04-02       Impact factor: 4.398

7.  Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort study.

Authors:  Alberto Martínez-Castelao; José L Górriz; José M Portolés; Fernando De Alvaro; Aleix Cases; José Luño; Juan F Navarro-González; Rafael Montes; Juan J De la Cruz-Troca; Aparna Natarajan; Daniel Batlle
Journal:  BMC Nephrol       Date:  2011-10-05       Impact factor: 2.388

8.  Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts.

Authors:  Yukiko Komano; Toshihiro Nanki; Kenji Hayashida; Ken Taniguchi; Nobuyuki Miyasaka
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

9.  Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors.

Authors:  F Arai; T Miyamoto; O Ohneda; T Inada; T Sudo; K Brasel; T Miyata; D M Anderson; T Suda
Journal:  J Exp Med       Date:  1999-12-20       Impact factor: 14.307

10.  RANK, RANKL and osteoprotegerin in bone biology and disease.

Authors:  H L Wright; H S McCarthy; J Middleton; M J Marshall
Journal:  Curr Rev Musculoskelet Med       Date:  2009-03-10
View more
  1 in total

1.  Prognostic alternative splicing signature in cervical squamous cell carcinoma.

Authors:  Hua-Yu Wu; Qi-Qi Li; Liang Liang; Lan-Lan Qiu; Hong-Wei Wei; Bing-Ying Huang; Chen Gang-; Rong-Quan He; Zhi-Guang Huang; Wei Hou; Qi-Ping Hu; Shang-Ling Pan
Journal:  IET Syst Biol       Date:  2020-12       Impact factor: 1.615

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.